eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Sara M. Tolaney(Harvard University), Shom Goel(Dana-Farber Cancer Institute), Yanyun Chen(Eli Lilly (United States)), Karla Hurt(Eli Lilly (United States)), Eva Ciruelos(Hospital Universitario 12 De Octubre), Lesley Fallowfield(Brighton and Sussex Medical School), M. Corona Gainford(Eli Lilly (United States)), Peter A. Kaufman(University of Vermont), Yi Lu(Shandong Provincial Hospital), Heather Wasserstrom(Eli Lilly (United States))
Cited by 1
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k